Aug 11, 2020
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
Jun 18, 2020
Aridis Pharmaceuticals to Discuss APEX(TM) in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
Jun 15, 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
May 12, 2020
Aridis Pharmaceuticals Announces First Quarter 2020 Results
May 04, 2020
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)
Apr 29, 2020
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
Mar 06, 2020
Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns
Mar 05, 2020
Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference
Mar 04, 2020
Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
Feb 18, 2020
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX(TM) Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
Jan 28, 2020
Aridis Pharmaceuticals Presents APEX(TM) Antibody Discovery and Production Platform Technology at the 19th Annual CHI PepTalk Conference
Oct 11, 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Sep 30, 2019
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
Sep 27, 2019
Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek(TM) 2019
Sep 27, 2019
Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 08, 2019
Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
Sep 03, 2019
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
Jul 30, 2019
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
Jul 19, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Jun 27, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501